Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.
Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.
The electronic medicines compendium (emc) no longer publishes a Summary of Product Characteristics for this product, which usually means it is no longer marketed in the UK. The patient leaflet below is kept for reference, but the product may not be available.
If you were prescribed this medicine, other products containing Lactic acid, Salicylic acid may still be available. Do not stop your treatment — ask your pharmacist or GP what to use instead.
Salatac Gel 4. Possible side effects 5. How to store Salatac Gel
SALATAC GEL
6. CONTENTS OF THE PACK AND OTHER INFORMATION What Salatac Gel contains: The active ingredients are salicylic acid (12.0% w/w) and lactic acid (4.0% w/w). The other ingredients are camphor, pyroxylin (contains isopropyl alcohol as a damping solvent), ethanol and ethyl acetate. What Salatac Gel looks like and contents of the pack The product is a clear colourless gel. The product is available in a tube containing 8 g of gel. The tube has a special applicator nozzle. Each pack also includes an emery board. Marketing Authorisation holder Dermal Laboratories, Hitchin, Herts, SG4 7QR. Manufacturer Aeropak, Viking Road, Great Yarmouth, Norfolk, NR31 0NU, UK. This Leaflet was last revised in July 2025. To listen to or request a copy of this leaflet in Braille, large print or audio, please call free of charge: 0800 198 5000 (UK only). Please be ready to give the following information: Salatac Gel, 00173/0046. This is a service provided by the Royal National Institute of Blind People (RNIB).
Like all medicines, Salatac Gel can cause side effects although not everybody gets them:
WP4/25/2 202874
A. Soak the affected area in warm water for 2 to 3 minutes. B. Dry the area thoroughly, using your own towel if you have a wart or verruca (this will help stop the infection spreading to other people). C. Taking care to avoid squeezing the tube, remove the protective cap, leaving the nozzle attached to the tube.
D. Carefully apply a thin coating (one or two drops) of the gel to the top of the wart, verruca, corn or callus only:
Salatac Gel comes as gel. Always follow the dose your doctor or pharmacist has given you, and read the leaflet that comes with the medicine.
The active substance in Salatac Gel is lactic acid, salicylic acid.
Medicines with the same active substance, strength and form include: Bazuka Gel, Bazuka Treatment Gel. They are interchangeable only if your prescriber or pharmacist says so.
This leaflet reproduces the patient information leaflet approved for Salatac Gel, as published on the electronic medicines compendium (emc). The version printed inside your medicine’s packaging is the one that applies to you.
Whether a medicine is available over the counter or on prescription only depends on its licence. Check the leaflet, or ask your pharmacist — they can tell you straight away.
The text above reproduces the patient information leaflet approved for this medicine, restructured for easier reading.
For the topical treatment of warts, verrucas, corns and calluses.
For adults, children and the elderly.
Salatac Gel should be applied once daily. The gel should be applied once every night. Treatment can take up to twelve (12) weeks for resistant lesions to disappear, and it is necessary to persevere with the treatment.
1. Every night, soak the affected site in warm water for 2 to 3 minutes.
2. Dry thoroughly with the patient's own towel.
3. Carefully apply one or two drops of the gel to the lesion and allow to dry over its surface. Take care to avoid spreading on to surrounding normal skin. No adhesive plaster is necessary.
4. The following evening, carefully remove and discard the elastic film formed from the previous application, and reapply the gel. Occasionally, if removal of the elastic film proves difficult, carefully reapply the gel directly over it and allow to dry. This should help thicken the film to assist removal. If necessary, such re-application may be made on two or three successive days.
5. Once a week, gently rub away the treated surface using an emery board, as provided, or pumice stone used only for this purpose, before re-applying the gel.
6. The wart, verruca, corn or callus may take up to twelve (12) weeks to disappear and it is important to persevere with the treatment.
7. At the end of treatment, if the elastic film is difficult to remove, it may be allowed to remain on the skin until it sheds.
Not to be used on or near the face, intertriginous or anogenital regions, or by diabetics or individuals with impaired peripheral blood circulation. Not to be used on moles or on any other skin lesions for which the gel is not indicated.
Not to be used in cases of sensitivity to any of the ingredients.
Keep away from the eyes, mucous membranes and from cuts and grazes.
The gel should be applied carefully to the wart, verruca, corn or callus only, to avoid possible irritation of surrounding normal skin.
Do not use excessively.
Some mild, transient irritation may be expected, but in cases of more severe or persistent pain/irritation, the treatment should be suspended and/or discontinued. See also Section 4.8.
Avoid inhaling vapour, and keep cap firmly closed when not in use.
Contact with clothing, fabrics, plastics and other materials may cause damage, and should be avoided.
For external use only.
Keep all medicines out of the reach of children.
None known.
There are no or limited amount of data from the use of Salatac Gel during pregnancy.
Salatac Gel should not be used during pregnancy, except for short-term treatment of a small single wart, verruca, corn or callus.
It is not known if the systemic Salatac Gel exposure reached after topical administration can be harmful to an embryo/fetus.
During the third trimester of pregnancy, systemic use of prostaglandin synthetase inhibitors may induce cardiopulmonary and renal toxicity in the fetus. At the end of the pregnancy prolonged bleeding time in both mother and child may occur, and labour can be delayed.
None known.
Salatac Gel may be irritant in certain patients, which in rare instances may appear as a temporary blemish on the skin. See also Section 4.4.
Reporting of suspected adverse reactions
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.
Any excessive use of Salatac Gel could cause irritation of the skin. If this occurs, Salatac Gel should be used more sparingly or applied less frequently.
Ask anything about Salatac Gel. The assistant answers only from this leaflet — if the leaflet does not cover it, it will say so. It does not give medical advice.
Answers come from the patient leaflet published on the electronic medicines compendium (emc). They are not medical advice. Ask a pharmacist or your GP if you are unsure. For urgent help call NHS 111, or 999 in an emergency.
We use essential cookies to make the site work. We would also like to set optional cookies to understand how the site is used, so we can improve it. We will not set optional cookies unless you accept. See our cookie policy and privacy policy.